Eptifibatide

Indications
 Intravenous
Unstable angina
Adult: 180 mcg/kg via IV inj followed by 2 mcg/kg per minute by IV infusion for up to 72 hr. If percutaneous coronary intervention (PCI) is performed during therapy, infusion should be continued for 18-24 hr after procedure, up to a maximum total duration of 96 hr of therapy.
Renal impairment: Dose reduction may be needed. See Lit.
CrCl (ml/min)Dosage Recommendation
<30Contraindicated.

Intravenous
Angioplasty
Adult: Initially, 180 mcg/kg via IV inj, to be given immediately before procedure, followed by 2 mcg/kg/minute via IV infusion. A second dose of 180 mcg/kg via IV inj should be given 10 minutes after the 1st dose. Continue infusion until hospital discharge or for up to 18-24 hr (minimum treatment duration: 12 hr).
Renal impairment: Dose reduction may be needed. See Lit.
CrCl (ml/min)Dosage Recommendation
<30Contra-indicated.


Special Populations: Dose reduction in renal impairment.
Contraindications
 Active bleeding, increased risk of haemorrhage including hemorrhagic disorders, cerebrovascular disorders, history of stroke, uncontrolled hypertension, severe trauma, severe renal impairment, recent major surgery. Lactation.
Warnings / Precautions
 Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic therapy is required. Hepatic impairment, platelet counts <100,000 mm3; hemorrhagic retinopathy, drugs affecting haemostasis. Check aPTT or ACT prior to sheath removal. Severe renal impairment, vasculitis, haemorrhagic retinopathy, acute pericarditis or aortic dissection. Pregnancy.
Adverse Reactions
 Bleeding, hypotension; localised Injection site reaction; thrombocytopaenia; back pain; anaphylaxis; GI, intracranial or pulmonary haemorrhage.
Drug Interactions
 Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.
See Below for More eptifibatide Drug Interactions
Mechanism of Actions
 Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor thus preventing platelet aggregation and thrombosis. [PubMedID: 21211597]
Onset: Within 1 hr.
ATC Classification
 B01AC16 - eptifibatide ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Available As
  • Eptifibatide 2 mg
  • Eptifibatide 75 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Eptifibatide


    Eptifibatide Containing Brands

    We are Developing Our database, More results coming soon.

    Eptifibatide is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Eptifibatide

    We are Developing Our database, More results coming soon.